16Jun
Diligence Clauses and the Management of Uncertainty in Life Sciences Agreements
In times of uncertainty and disruption, setting expectations for performance with business partners and contractual counterparties can be more complicated than ever. Companies that develop drugs, biologics and medical devices have considerable...
By:
Skadden, Arps, Slate, Meagher & Flom LLP
Related
On May 3, 2019, the SEC issued a proposal to amend certain rules and forms relating to required fina...
Read More >
On February 1, 2021, the Federal Trade Commission (FTC) announced the annual changes to the Hart-Sco...
Read More >
The assault on arbitration is old news. Recently, however, courts and commentators alike have seemed...
Read More >
On June 5, 2019, the Securities and Exchange Commission (“SEC”) adopted a final version of the Reg...
Read More >
On January 12, 2020, the United States Department of Labor ("USDOL") Wage and Hour Division announce...
Read More >
With some Canada Labour Code (CLC) amendments in Bill C-44, the Budget Implementation Act, 2017, No....
Read More >